Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biphenyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL27760037 | 0.97 | ALDH1A1 (0.56) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL27720670 | 0.97 | ALDH1A1 (0.64) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL28027750 | 0.91 | ALDH1A1 (0.50) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL3453455 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL28325969 | 0.87 | ALDH1A1 (0.45) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL10773004 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Piperazine SCHEMBL17065814 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL8466409 | 0.84 | ACP3 (0.47) | ALDH1A1HTR1AHTR7SIGMAR1CYP1A2 | |
| Biphenyl SCHEMBL28051011 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C | |
| Biphenyl SCHEMBL29176815 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HTR1AHTR7SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138713-A | Stearylamine modified ammonium polyphosphate and preparation method and application thereof | 上海普利特复合材料股份有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-107556255-A | A kind of organic amine modified melamine polyphosphate and preparation method thereof | 东华大学 | 2018-01-09 | — | — | CN | claimed |
| CN-107459492-A | A kind of organically-modified melamine polyphosphate and preparation method thereof | 东华大学 | 2017-12-12 | — | — | CN | claimed |
| CN-117586179-A | GPR183 antagonist and synthetic method and application thereof | 中国人民解放军海军特色医学中心 | 2024-02-23 | — | — | CN | disclosed |
| CN-110498789-B | Aralkyl piperidine derivative and application thereof in multi-target anti-depression | 上海医药工业研究院 | 2022-04-05 | — | — | CN | disclosed |
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | TWINCORE ZENTRUM FUR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
| CN-110713470-B | Flunarizine hydrochloride crystal form B and preparation method thereof | 迪嘉药业集团有限公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3898593-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-112209917-B | Application of heterocyclic substituted phenylpiperazine or phenylpiperidine derivatives in antidepressant drugs | 上海医药工业研究院 | 2021-09-24 | — | — | CN | disclosed |
| CN-112209917-A | Application of heterocyclic substituted phenyl piperazine (pyridine) derivatives in antidepressant drugs | 上海医药工业研究院 | 2021-01-12 | — | — | CN | disclosed |
| WO-2020127211-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-06-25 | — | — | WO | disclosed |
| CN-1392140-A | Organic compound with bis-4-dicyanomethylene pyran ring and synthetic method and application thereof | PHYSICAL & CHEMICAL TECHNOLOGY (CN) | 2003-01-22 | — | — | CN | disclosed |
| CN-1332727-A | 3, 3-diarylpiperidine and 2, 2-diarylmorpholine derivatives | PFIZER PROD INC (US) | 2002-01-23 | — | — | CN | disclosed |
| EP-1053745-A1 | Use of at least a calcium-channel-inhibitor in the treatment of wrinkles | L'OREAL (FR) | 2000-11-22 | — | — | EP | disclosed |
| CN-1054850-C | Piperazine compounds used in therapy | WELLCOME FOUND (GB) | 2000-07-26 | — | — | CN | disclosed |
| CN-1251520-A | Use of sodium channel blocker in manfacture of medicament for preventing optic nerve degeneration associated with glaucoma | ALLERGAN SALES INC (US) | 2000-04-26 | — | — | CN | disclosed |
| CN-1196732-A | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | SEARLE & CO (US) | 1998-10-21 | — | — | CN | disclosed |
| CN-1133593-A | Piperazine compounds for use in therapy | WELLCOME FOUND (GB) | 1996-10-16 | — | — | CN | disclosed |
| US-4309511-A | COBALT COMPOUND, COPPER COMPOUND, AND HETEROCYCLIC AMINE | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1982-01-05 | — | — | US | disclosed |
| US-3953448-A | CORONARY VASODILATION | DELMAR CHEMICALS LIMITED (CA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | HAVCR2, HCCS, HELZ | ALDH1A1 701/4885HTR1A 797/4885HTR7 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.